1. The Effects of Inhaled Terbutaline on 3-km Running Time-Trial Performance.
- Author
-
Molphy, John, Dickinson, John W., Chester, Neil J., Loosemore, Mike, and Whyte, Gregory
- Subjects
DRUG therapy for asthma ,ATHLETIC ability ,BODY weight ,EXERCISE physiology ,INFORMED consent (Medical law) ,LACTATES ,RESPIRATORY diseases ,STATURE ,TREADMILLS ,ERGOGENIC aids ,RANDOMIZED controlled trials ,LONG-distance running ,VITAL capacity (Respiration) ,BLIND experiment ,INHALATION administration ,TERBUTALINE ,ONE-way analysis of variance ,THERAPEUTICS - Abstract
Terbutaline is a prohibited drug except for athletes with a therapeutic use exemption certificate; terbutaline's effects on endurance performance are relatively unknown. Purpose: To investigate the effects of 2 therapeutic (2 and 4 mg) inhaled doses of terbutaline on 3-km running time-trial performance. Methods: A total of 8 men (age 24.3 [2.4] y; weight 77.6 [8] kg; and height 179.5 [4.3] cm) and 8 women (age 22.4 [3] y; weight 58.6 [6] kg; and height 163 [9.2] cm) free from respiratory disease and illness provided written informed consent. Participants completed 3-km running time trials on a nonmotorized treadmill on 3 separate occasions following placebo and 2- and 4-mg inhaled terbutaline in a single-blind, repeated-measures design. Urine samples (15 min postexercise) were analyzed for terbutaline concentration. Data were analyzed using 1-way repeated-measures analysis of variance, and significance was set at P < .05 for all analyses. Results: No differences were observed for completion times (1103 [201] s, 1106 [195] s, 1098 [165] s; P = .913) for the placebo or 2- and 4-mg inhaled trials, respectively. Lactate values were higher (P = .02) after 4 mg terbutaline (10.7 [2.3] mmol⋅L
-1 ) vs placebo (8.9 [1.8] mmol⋅L-1 ). Values of forced expiratory volume in the first second of expiration (FEV1 ) were greater after inhalation of 2 mg (5.08 [0.2]; P = .01) and 4 mg terbutaline (5.07 [0.2]; P = .02) compared with placebo (4.83 [0.5] L) postinhalalion. Urinary terbutaline concentrations were mean 306 (288) ng⋅mL-1 and 435 (410) ng⋅mL-1 (P = .2) and peak 956 ng⋅mL-1 and 1244 ng⋅mL-1 after 2 and 4 mg inhaled terbutaline, respectively. No differences were observed between the male and female participants. Conclusions: Therapeutic dosing of terbutaline does not lead to an improvement in 3-km running performance despite significantly increased FEV1 . The findings suggest that athletes using inhaled terbutaline at high therapeutic doses to treat asthma will not gain an ergogenic advantage during 3-km running performance. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF